SEC-sourced researchBeta
AMRX
Amneal Pharmaceuticals, Inc.
Company comparison ↗
Data passport
- CIK
- 0001723128
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 5/6
- Filing date
- Sep 21, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 2,393,607,000.0000 | Feb 27, 2026 |
| December 2024 | 2,793,957,000.0000 | Feb 27, 2026 |
| December 2025 | 3,018,760,000.0000 | Feb 27, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 3,018,760,000.0000 | 72,057,000.0000 | 339,992,000.0000 | 3,678,280,000.0000 | — | Feb 27, 2026 |
| December 2024 | 2,793,957,000.0000 | -116,886,000.0000 | 295,099,000.0000 | 3,501,445,000.0000 | — | Feb 27, 2026 |
| December 2023 | 2,393,607,000.0000 | -83,993,000.0000 | 345,577,000.0000 | — | — | Feb 27, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenueFromContractWithCustomerExcludingAssessedTax | $3.02B | December 2025 | Feb 27, 2026 | 10-K |
| Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax | $2.79B | December 2024 | Feb 27, 2026 | 10-K |
| Net incomeNetIncomeLoss | $72.06M | December 2025 | Feb 27, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $339.99M | December 2025 | Feb 27, 2026 | 10-K |
| Total assetsAssets | $3.68B | December 2025 | Feb 27, 2026 | 10-K |
| Total liabilities | — | — | — | — |